Dr. Sue Sisley from the Arizona-based Scottsdale Research Institute (SRI) conducted a clinical trial in 2018/2019 to determine marijuana’s potential in helping people with PTSD. Due to her marijuana-related research she has spent years battling with the Drug Enforcement Administration (DEA) to obtain marijuana to use in her clinical trials. It has been an uphill battle, but her efforts are making progress.
The DEA disclosed a memo last week as part of a settlement agreement with SRI, Reason reported. According to the 2018 memo, the Justice Department’s Office of Legal Counsel (OLC) believes the DEA has had an illegal, 47-year monopoly on cultivating and distributing marijuana that is used for research purposes in the United States.
The memo explains why the DEA has been so reluctant in following through on its 2016 commitment to allow for more than one government-contracted marijuana supplier.
In order to simplify the process, Dr. Sisley recommended that the DEA could, for example, “exempt licensed Schedule I marijuana researchers from having to obtain a separate registration to manufacture marijuana, provided those researchers agree not to distribute any marijuana they manufacture.” Or, better yet, she says, “it could permit licensed Schedule I marijuana researchers to obtain marijuana from state-legal dispensaries.”
It has been a years-long battle between researchers and the governmental agencies. Progress is slow, but at least there is progress — thanks to people like Dr. Sisley.
As of now, it appears the DEA is finally moving forward with allowing additional marijuana suppliers for researchers in the U.S.
Joe Ahlquist, The Argus Leader via AP